Zu Inhalt springen
View in the app

A better way to browse. Learn more.

Psoriasis-News

A full-screen app on your home screen with push notifications, badges and more.

To install this app on iOS and iPadOS
  1. Tap the Share icon in Safari
  2. Scroll the menu and tap Add to Home Screen.
  3. Tap Add in the top-right corner.
To install this app on Android
  1. Tap the 3-dot menu (⋮) in the top-right corner of the browser.
  2. Tap Add to Home screen or Install app.
  3. Confirm by tapping Install.

Psoriasis im JDDG

46 Artikel in dieser Kategorie

  1. Redaktion ·
    No abstract supplied.Weiterlesen
    • 173 Aufrufe
  2. Redaktion ·
    Background There are only limited histomorphological data on the response of psoriatic skin lesions to topical dithranol. In vivo reflectance confocal microscopy (RCM) in psoriatic skin is highly correlated with histopathological findings and allows non-invasive monitoring of treatment effects on a cellular level.Patients and methods Prospective, single-center pilot study at a university-based clinic of dermatology between January 1st and August 30th, 2016. Psoriatic lesions of 20 patients recei
    • 101 Aufrufe
    • 126 Aufrufe
  3. Redaktion ·
    No abstract supplied.Weiterlesen
    • 93 Aufrufe
  4. Redaktion ·
    Background The pathogenesis of nummular eczema (NE) remains unclear, and no targeted therapy has been approved. Apremilast is a small molecule inhibitor targeting phosphodiesterase-4.Patients and methods A phase IIb randomized, double-blind, placebo-controlled study evaluating the effects of apremilast or placebo in patients with NE. Patients received apremilast (30 mg BID) or placebo until week 16 followed by an open label phase in which all patients were treated with apremilast until week 32.
    • 97 Aufrufe
  5. Redaktion ·
    No abstract supplied.Weiterlesen
    • 89 Aufrufe
  6. Redaktion ·
    No abstract supplied.Weiterlesen
    • 69 Aufrufe
  7. Redaktion ·
    No abstract supplied.Weiterlesen
    • 75 Aufrufe
  8. Redaktion ·
    Background and objectives Continuous biologic treatment is recommended for patients with psoriasis; however, treatment interruption in daily practice is inevitable. The impact of treatment interruption is difficult to study in a real-world setting. In Taiwan, biologics are reimbursed by the National Health Insurance for moderate-to-severe psoriasis for a 2-year course, followed by regulatory discontinuation. Thus, our study provides pragmatic data on the impact of the interruption of biologics t
    • 162 Aufrufe
  9. Redaktion ·
    No abstract supplied.Weiterlesen
    • 112 Aufrufe
  10. Redaktion ·
    Gluten-related disorders (GRDs) encompass a spectrum of clinical manifestations triggered by gluten ingestion in genetically susceptible individuals. These disorders include celiac disease (CD) and non-celiac gluten sensitivity (NCGS) and present with both intestinal and extraintestinal symptoms, including skin manifestations. Besides the well-known association between CD and dermatitis herpetiformis, considered as the cutaneous manifestation of CD, other dermatoses have been associated to GRDs.
    • 101 Aufrufe
  11. Redaktion ·
    No abstract supplied.Weiterlesen
    • 116 Aufrufe
  12. Redaktion ·
    Tuberculosis (TB) continues to be a leading cause of death in many countries, and also remains a significant concern in Germany, particularly due to migration. The diagnosis of rare cutaneous tuberculosis is challenging as it manifests in various clinical forms that resemble more common dermatological conditions. Especially in paucibacillary forms, gold-standard diagnostic tests may yield negative results, complicating the identification of the disease. Therefore, a strong clinical suspicion bas
    • 124 Aufrufe
  13. Redaktion ·
    No abstract supplied.Weiterlesen
    • 114 Aufrufe
  14. Redaktion ·
    Background and objectives Knowledge on patient care gaps of prurigo nodularis (PN) is limited. This retrospective chart review (ADVANCE PN) investigated unmet medical needs and gaps in diagnostics, treatment, and management of patients with PN in routine care in Germany.Patients and methods Medical records for adults newly diagnosed with PN between January 2012 and December 2022 from dermatologic clinics and office-based dermatologists were analyzed. Baseline demographics, treatment patterns, di
    • 126 Aufrufe
    • 140 Aufrufe
    • 168 Aufrufe
  15. Redaktion ·
    Background and objectives Flexible biologic therapy dosing regimens in psoriasis management are common, but data from routine care in Germany are scarce. This study evaluated treatment adjustments for biologic therapies commonly prescribed in Germany.Patients and methods Charts for up to 100 consecutive patients treated at 29 centers were reviewed. Data were extracted for adults (aged 18-65 years) with moderate-to-severe plaque psoriasis treated with adalimumab, guselkumab, ixekizumab, secukinum
    • 177 Aufrufe
  16. Claudia ·
    Background and objective Erosions of the skin and mucous membranes with epidermal dysmaturation are a known side effect of cytostatic chemotherapy regimens and can also be observed during low-dose methotrexate (MTX) therapy. The study aimed to delineate the clinical and histopathological alterations.Patients and methods A database search of the archive for dermatopathology was conducted, identifying 22 patients who developed epidermal dysmaturation on low-dose MTX. Clinical and laboratory change
    • 174 Aufrufe
  17. Claudia ·
    Objective To construct a predictive model for Psoriatic Arthritis (PsA) based on clinical and ultrasonic characteristics in patients with plaque psoriasis (PsP).Patients and methods Demographic, clinical, and ultrasound data were collected from patients with PsP and PsA between May 2019 and December 2022.Results A total of 212 patients with PsP and 123 with PsA in the training cohort, whereas the validation cohort comprised 91 patients with PsP and 49 with PsA. The multivariate logistic regressi
    • 158 Aufrufe

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.